BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:The Milner Therapeutics Institute: A new vehicle to facilitate aca
 demic/industry interactions in Cambridge - Prof Tony Kouzarides\, Universi
 ty of Cambridge
DTSTART:20160620T150000Z
DTEND:20160620T160000Z
UID:TALK66369@talks.cam.ac.uk
CONTACT:Dr Kathryn Chapman
DESCRIPTION:Prof Tony Kouzarides will give a short presentation to highlig
 ht opportunities for academics to collaborate with pharmaceutical and biot
 ech companies\, facilitated by the Milner Institute. \n\nThe talk will be 
 followed by wine and networking.\n\nThe mission of the Milner Therapeutics
  Institute is to connect the intellectual know-how of academic institution
 s in Cambridge with the drug-development capacity of industry to deliver b
 etter therapies. \n\nThis will be achieved through:\n\n- A world-leading T
 herapeutics Institute dedicated to the conversion of science into therapie
 s \n- An outreach programme\, the Therapeutics Consortium\, which will (a)
  connect laboratories throughout Cambridge with industry and (b) develop i
 nnovative projects to be considered for joint funding by industry. \n\nThe
 rapeutics Institute. The Institute will house independent research groups\
 , still to be appointed\, in the new Capella building currently under cons
 truction on the Biomedical Campus. The Institute will also house a communa
 lly accessible core facility\, which will be available to academic and ind
 ustry partners of the Consortium. The Institute is expected to be operatio
 nal in 2018. \n\nTherapeutics Consortium. This represents the outreach pro
 gramme of the Institute. It has been active since June 2015 and currently 
 operates from the Gurdon Institute but will be housed at the Milner Instit
 ute when completed. The consortium is based on an agreement signed by thre
 e academic centers in Cambridge\, (Cambridge University\, Sanger Institute
  and Babraham Institute) and four pharmaceutical companies (Astex\, AstraZ
 eneca\, GlaxoSmithKline and Shionogi).\n\nThe key features of the consorti
 um are:\n\n- An agreement to facilitate the speedy exchange of reagents an
 d information between partners in all therapeutic areas\n- The appointment
  of a dedicated executive to oversee academic/company project engagement\n
 - The development of innovative ideas that would push forward therapeutic 
 boundaries\, which will be considered for common funding by industrial par
 tners.\n\nThe outreach program of the Institute also involves an Affiliate
 d Company Partnership Scheme\, which allows engagement with service and pr
 oduct providers (both local and international) that are developing tools t
 o advance therapeutic development. The Institute will encourage and coordi
 nate interactions of affiliated companies with the pharmaceutical and acad
 emic partners\, towards communal project development. \n\nPlease come and 
 hear how you can benefit from the outreach program of the Milner Therapeut
 ics Institute.\n
LOCATION:Dept of Pharmacology
END:VEVENT
END:VCALENDAR